Myelodysplastic Syndrome, Flow Cytometry, Bone Marrow
Use
This test is useful for detecting increased blasts, characterizing blast phenotypes, and identifying abnormal patterns of myeloid maturation as seen in myelodysplastic syndromes and other clonal myeloid neoplasms. It provides additional diagnostic information in cases with equivocal or suspicious morphological features for conditions like myelodysplastic syndrome (MDS), MDS/myeloproliferative neoplasms including chronic myelomonocytic leukemia, and other clonal myeloid neoplasms.
Special Instructions
This assay should be used in conjunction with clinical history, morphologic, cytogenetic, and molecular genetic data. It is not intended for prognostication or monitoring of therapy response.
Limitations
The results need correlation with the patient's clinical history, morphologic review, and other laboratory features. This assay should not be standalone for diagnosis or subclassification of related conditions. It also should not be used for therapy monitoring. There is a requirement for additional specimen submission if cytogenetic tests are also desired.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
LOINC Codes
- 22637-3
- 30954-2
- 22635-7
Result Turnaround Time
1-4 days
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
2-5 mL
Minimum Volume
1 mL
Container
Preferred: Yellow top (ACD solution A or B); Acceptable: Lavender top (EDTA), green top (heparin)
Collection Instructions
Submission of bilateral specimens is not required. Send bone marrow specimen in original tube. Do not aliquot. Label specimen as bone marrow.
Causes for Rejection
Gross hemolysis